Home » Polycystic Ovary Syndrome (PCOS) Market

Polycystic Ovary Syndrome (PCOS) Market By Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, Others) By End User (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online pharmacies) – Growth, Future Prospects & Competitive Analysis, 2016 – 2028

Price: $4999

Published: | Report ID: 10015 | Report Format : PDF

About this report

The global Polycystic Ovary Syndrome (PCOS) Market report explores the critical analysis of the Polycystic Ovary Syndrome (PCOS) industry using key parameters. The report consists of investment strategies, the need for investments in the Polycystic Ovary Syndrome (PCOS) industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the Polycystic Ovary Syndrome (PCOS) industry, as well as how economic and non-economic barriers are helping the Polycystic Ovary Syndrome (PCOS) market grow. Moreover, the report analyzes the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses such as porter’s five forces analysis, PESTEL analysis, value chain analysis, etc.

Key Highlights of the report

How are the major segments performing in the Polycystic Ovary Syndrome (PCOS) Market?

In 2021, the Insulin Sensitizing Agent segment was the leading segment by drug class. Due to their ability to balance hormone levels, reduce ovarian androgen production, and lower insulin levels, insulin-sensitizing drugs are crucial in therapies.

In 2021, the hospital pharmacies led the polycystic ovary syndrome (PCOS) market by end users. Patients always purchase medicines for serious disorders such as polycystic ovary syndrome (PCOS) based on doctors’ recommendations in hospitals.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Which region dominated the Polycystic Ovary Syndrome (PCOS) Market?

In 2021, the market for treating polycystic ovarian syndrome (PCOS) will be dominated by North America due to the region’s high level of awareness and accessibility to cutting-edge medical facilities. Due to government measures to increase awareness of the signs and symptoms of PCOS, the diagnosis of this syndrome among women in the region, and the treatments that are accessible, Asia-Pacific is predicted to have high growth during the forecast period.

What is the competitive environment of the Polycystic Ovary Syndrome (PCOS) Market?

The Polycystic Ovary Syndrome (PCOS) industry’s competitive environment offers information on the total economic profit made by suppliers and businesses, the sales and revenues produced in this sector, the polycystic ovary syndrome (PCOS) market share globally, the business organization overview, the introduction of new products, and the opportunities for the polycystic ovary syndrome (PCOS) market. Players in the market are focused on developing effective treatments for PCOS. For instance, Abbvie was conducting a clinical trial in women with the polycystic ovarian syndrome to determine the effectiveness and safety of the drug Elagolix in January 2020. Elagolix’s safety and effectiveness in treating women with polycystic ovarian syndrome are currently being examined in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study by the company (PCOS).

Executive Summary

What opportunities are for major players in the Polycystic Ovary Syndrome (PCOS) Market?

Most insurance and coverage plans do not cover the cost of drugs used to treat the polycystic ovarian syndrome. Few medications have rather high costs. Adopting polycystic ovarian syndrome medications would benefit from a decrease in the price of branded medications. Only Metformin, an insulin sensitizer, is now on the list of medications that are reimbursed. Drugs for polycystic ovarian syndrome may be covered by reimbursement policies, which would help spur the expansion of the insulin-sensitizing agent’s drug class segment, given the high cost of insulin-sensitizing agents in various countries. The development of novel medications to treat polycystic ovarian syndrome is expected to get increased support from government bodies and funding organizations, which will benefit market participants.

Which are the key investments by the players in the Polycystic Ovary Syndrome (PCOS) Market?

Various investments are made throughout by key players through innovation, development of effective treatments, and through strategic collaboration or acquisition. For instance, Abbvie was conducting a clinical trial using the drug Elagolix in women with the polycystic ovarian syndrome in January 2020 to determine its safety and effectiveness. The company is now conducting a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to assess Elagolix’s safety and effectiveness in treating women with polycystic ovarian syndrome (PCOS). To develop multiple clinical candidates for the treatment of polycystic ovarian syndrome, which is anticipated to lead the market throughout the projection period, Evotec S.E. and Bayer AG announced a new five-year multi-target cooperation with Celmatix Inc. in January 2020.

Some of the major players in the market are Allergan plc, AstraZeneca plc, Bayer AG., Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, Teva Pharmaceutical Industries and others.

What are the Major Driving Factors for the Polycystic Ovary Syndrome (PCOS) Market?

Many women of childbearing age experience the hormonal disease of a polycystic ovarian syndrome (PCOS). Menstrual cycles that are irregular or lengthy and increased levels of male hormones are symptoms of polycystic ovary syndrome (PCOS). The market for treating polycystic ovarian syndrome (PCOS) will profit from the rising prevalence of the condition since there will be greater demand for appropriate treatments and pharmaceuticals due to the increased cases of the polycystic ovarian syndrome. As per the Centers for Disease Control and Prevention, Polycystic Ovarian Syndrome affects about 5 million women of reproductive age. Therefore, the increase in cases will immediately present chances for the market to develop profitably during the forecast period.

What Major Risks for the Polycystic Ovary Syndrome (PCOS) Market?

There are several negative effects associated with polycystic ovary syndrome medications. Drug-related side effects include increased insulin resistance, altered glucose tolerance, weight gain, and thromboembolic events predicted to hinder market expansion. The market for treating polycystic ovarian syndrome (PCOS) is expected to have challenges during the forecast period due to a shortage of FDA-approved drugs and approved treatments.

Which is the key drug class in the Polycystic Ovary Syndrome (PCOS) Market?

The largest section consists of insulin-sensitizing agents. Numerous drugs are sold, including Glucophage X.R. (Metformin) and other items containing Troglitazone, Rosiglitazone, and Pioglitazone. Metabolic dysfunction in PCOS may cause an overproduction of androgen, impacting insulin secretion and raising the risk of diabetes. As a result, insulin-sensitizing drugs are crucial for therapies because they balance hormone levels, lower insulin levels, and reduce ovarian androgen production. The market for oral contraceptive pills (OCPs) is anticipated to develop faster. Ethinyl Estradiol, Medroxyprogesterone Acetate, and Drospirenone make up the most commercially available oral contraceptive products. These OCPs treat the symptoms of the polycystic ovarian syndrome, such as acne, severe menstrual pain, PMS, and irregular or nonexistent menstrual cycles. As a result, it is anticipated that demand for OCPs would grow at the quickest rate over the projected period.

How is the Polycystic Ovary Syndrome (PCOS) Market performing in regions?

In 2021, the global Polycystic Ovary Syndrome (PCOS) market was dominated by North America. The most developed market is North America, followed by Europe. One of the major factors driving the market growth in North America is the rise in PCOS cases due to rising rates of obesity and overweight. In addition, more people are becoming aware of the advantages of routine checkups, increasing the number of new cases detected here each year. The United States dominates the North American market with the highest revenue share. This market is expanding mostly due to this nation’s huge number of PCOS sufferers. Furthermore, it is projected that the U.S.’s ability to attract large market participants like Merck, Abbott, and BMS will substantially impact the nation’s ability to generate income.

China and India comprise most of the population in the Asia Pacific region. As a result, the region’s PCOS treatment market has tremendous growth potential due to a sizable target patient pool. The governments of these nations are concentrating on reducing the rising prevalence of PCOS by implementing initiatives that promote the diagnosis, treatment, and necessary lifestyle change of this syndrome. These initiatives raise public awareness of PCOS and its hazards, including the emergence of insulin resistance, obesity, and occasionally infertility. Shortly, the Asia Pacific market is anticipated to be driven by these factors.

What is the regulatory landscape for the Polycystic Ovary Syndrome (PCOS) Market?

The FDA and EMA have not yet approved any medications to treat the polycystic ovarian syndrome, giving pharmaceutical companies a chance to control a sizeable portion of the market. The market for treating polycystic ovarian syndrome (PCOS) is expected to have difficulties due to a shortage of FDA-approved medications and approved treatments.

What is the Market Size of Polycystic Ovary Syndrome (PCOS) regarding value?

The global Polycystic Ovary Syndrome (PCOS) Market is anticipated to grow at a substantial CAGR of 8.4% in the upcoming years. The global Polycystic Ovary Syndrome (PCOS) treatment industry was estimated to be worth USD 3,519.4 million in 2021 and was expected to be worth USD 5,710.1 million by 2028.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

What are the major players planning for the future of the Polycystic Ovary Syndrome (PCOS) Market?

The leading competitors in the polycystic ovary syndrome (PCOS) market are substantially investing in technology developments for polycystic ovary syndrome detection, and it is anticipated that the increased awareness of polycystic ovarian syndrome therapy would provide lucrative market prospects. Important players are also concentrating on developing the unrealized potential of developing economies.

Segmentation of Global Polycystic Ovary Syndrome (PCOS) Market-

Global Polycystic Ovary Syndrome (PCOS) Market – By Drug Class

  • Insulin Sensitizing Agent
  • Oral Contraceptive
  • Antiandrogens
  • Anti-Obesity Drugs
  • Others

Global Polycystic Ovary Syndrome (PCOS) Market – By End User

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online pharmacies

Global Polycystic Ovary Syndrome (PCOS) Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Polycystic Ovary Syndrome (PCOS) Market
2.2. Global Polycystic Ovary Syndrome (PCOS) Market, By Drug Class
2.3. Global Polycystic Ovary Syndrome (PCOS) Market, By End User
2.4. Global Polycystic Ovary Syndrome (PCOS) Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Polycystic Ovary Syndrome (PCOS) Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Market Drivers
3.2.3. Market Restraints
3.2.4. Market Opportunities
3.2.5. Major Industry Challenges
3.3. Attractive Investment Proposition,2021
3.3.1. Product
3.3.2. Application
3.3.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Value Chain Analysis
4.4. Technology Analysis
4.5. Marketing Strategy Analysis
4.5.1. Direct Marketing
4.5.2. Indirect Marketing
4.5.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2021
5.1. Company market share of key players, 2021
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. COVID 19 Impact Analysis
6.1. Global Polycystic Ovary Syndrome (PCOS) Market Pre Vs Post COVID 19, 2019 – 2028
6.2. Impact on Import & Export
6.3. Impact on Demand & Supply

7. Global Polycystic Ovary Syndrome (PCOS) Market
7.1. Global Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028(US$ Bn)
7.1.1. Overview
7.1.2. Global Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2021 vs 2028 (in%)
7.1.3. Global Polycystic Ovary Syndrome (PCOS) Market, By Insulin Sensitizing Agent, 2016-2028 (US$ Bn)
7.1.4. Global Polycystic Ovary Syndrome (PCOS) Market, By Oral Contraceptive, 2016-2028 (US$ Bn)
7.1.5. Global Polycystic Ovary Syndrome (PCOS) Market, By Antiandrogens, 2016-2028 (US$ Bn)
7.1.6. Global Polycystic Ovary Syndrome (PCOS) Market, By Anti-Obesity Drugs, 2016-2028 (US$ Bn)
7.1.7. Global Polycystic Ovary Syndrome (PCOS) Market, By Others, 2016-2028 (US$ Bn)
7.2. Global Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Global Polycystic Ovary Syndrome (PCOS) Market, By End User, 2021 vs 2028 (in%)
7.2.3. Global Polycystic Ovary Syndrome (PCOS) Market, By Hospital Pharmacies, 2016-2028 (US$ Bn)
7.2.4. Global Polycystic Ovary Syndrome (PCOS) Market, By Drug Stores & Retail Pharmacies, 2016-2028 (US$ Bn)
7.2.5. Global Polycystic Ovary Syndrome (PCOS) Market, By Online pharmacies, 2016-2028 (US$ Bn)

8. North America Polycystic Ovary Syndrome (PCOS) Market Analysis
8.1. North America Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
8.3.1. U.S.
8.3.1.1. U.S. Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.3.1.2. U.S. Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
8.3.1.3. U.S. Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
8.3.2. Canada
8.3.2.1. Canada Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
8.3.2.2. Canada Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)

9. Europe Polycystic Ovary Syndrome (PCOS) Market Analysis
9.1. Europe Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
9.3.1. Germany
9.3.1.1. Germany Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.1.2. Germany Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
9.3.1.3. Germany Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
9.3.2. France
9.3.2.1. France Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.2.2. France Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
9.3.2.3. France Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
9.3.3. UK
9.3.3.1. UK Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.3.2. UK Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
9.3.3.3. UK Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
9.3.4. Italy
9.3.4.1. Italy Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.4.2. Italy Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
9.3.4.3. Italy Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
9.3.5. Spain
9.3.5.1. Spain Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.5.2. Spain Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
9.3.5.3. Spain Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
9.3.6. Rest of Europe
9.3.6.1. Rest of Europe Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.6.2. Rest of Europe Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
9.3.6.3. Rest of Europe Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)

10. Asia Pacific Polycystic Ovary Syndrome (PCOS) Market Analysis
10.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
10.3.1. China
10.3.1.1. China Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.1.2. China Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
10.3.1.3. China Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
10.3.2. Japan
10.3.2.1. Japan Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.2.2. Japan Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
10.3.2.3. Japan Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
10.3.3. India
10.3.3.1. India Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.3.2. India Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
10.3.3.3. India Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
10.3.4. South Korea
10.3.4.1. South Korea Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.4.2. South Korea Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
10.3.4.3. South Korea Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
10.3.5. South-East Asia
10.3.5.1. South-East Asia Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.5.2. South-East Asia Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
10.3.5.3. South-East Asia Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
10.3.6. Rest of Asia Pacific
10.3.6.1. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.6.2. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
10.3.6.3. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)

11. Latin America Polycystic Ovary Syndrome (PCOS) Market Analysis
11.1. Latin America Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Polycystic Ovary Syndrome (PCOS) Market, by Deployment, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. SRC Analysis
11.4. Latin America Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
11.4.1. Brazil
11.4.1.1. Brazil Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.4.1.2. Brazil Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
11.4.1.3. Brazil Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
11.4.2. Mexico
11.4.2.1. Mexico Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.4.2.2. Mexico Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
11.4.2.3. Mexico Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
11.4.3. Rest of Latin America
11.4.3.1. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.4.3.2. Rest of Latin America Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
11.4.3.3. Rest of Latin America Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)

12. Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market Analysis
12.1. Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, by Deployment, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
12.4.1. GCC Countries
12.4.1.1. GCC Countries Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.4.1.2. GCC Countries Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
12.4.1.3. GCC Countries Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
12.4.2. South Africa
12.4.2.1. South Africa Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.4.2.2. South Africa Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
12.4.2.3. South Africa Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)
12.4.3. Rest of Middle East and Africa
12.4.3.1. Rest of Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.4.3.2. Rest of Middle East and Africa Polycystic Ovary Syndrome (PCOS), By Drug Class, 2016-2028 (US$ Bn)
12.4.3.3. Rest of Middle East and Africa Polycystic Ovary Syndrome (PCOS), By End User, 2016-2028 (US$ Bn)

13. Company Profiles
13.1. Allergan plc
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2021)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. AstraZeneca plc
13.3. Bayer AG
13.4. Bristol-Myers Squibb Company
13.5. Johnson and Johnson
13.6. Mylan N.V
13.7. Novartis AG
13.8. Pfizer Inc
13.9. SANOFI
13.10. Teva Pharmaceutical Industries
13.11. Others

List of Figures

FIG. 1 Global Polycystic Ovary Syndrome (PCOS) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Polycystic Ovary Syndrome (PCOS) Market Segmentation
FIG. 4 Global Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2021 (US$ Bn)
FIG. 5 Global Polycystic Ovary Syndrome (PCOS) Market, By End User, 2021 (US$ Bn)
FIG. 6 Global Polycystic Ovary Syndrome (PCOS) Market, by Geography, 2021 (US$ Bn)
FIG. 7 Attractive Investment Proposition, By Drug Class, 2021
FIG. 8 Attractive Investment Proposition, By End User, 2021
FIG. 9 Attractive Investment Proposition, by Geography, 2021
FIG. 10 Global Market Share Analysis of Key Polycystic Ovary Syndrome (PCOS) Market Manufacturers, 2021
FIG. 11 Global Market Positioning of Key Polycystic Ovary Syndrome (PCOS) Market Manufacturers, 2021
FIG. 12 Global Polycystic Ovary Syndrome (PCOS) Market Value Contribution, By Drug Class, 2021 & 2028 (Value %)
FIG. 13 Global Polycystic Ovary Syndrome (PCOS) Market, by Insulin Sensitizing Agent, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Polycystic Ovary Syndrome (PCOS) Market, By Oral Contraceptive, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Polycystic Ovary Syndrome (PCOS) Market, By Antiandrogens, Value, 2016-2028 (US$ Bn)
FIG. 16 Global Polycystic Ovary Syndrome (PCOS) Market, By Anti-Obesity Drugs, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Polycystic Ovary Syndrome (PCOS) Market, By Others, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Polycystic Ovary Syndrome (PCOS) Market Value Contribution, By End User, 2021 & 2028 (Value %)
FIG. 19 Global Polycystic Ovary Syndrome (PCOS) Market, by Hospital Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 20 Global Polycystic Ovary Syndrome (PCOS) Market, by Drug Stores & Retail Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 21 Global Polycystic Ovary Syndrome (PCOS) Market, by Online pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 22 U.S. Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 23 Canada Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 24 Germany Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 25 France Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 26 U.K. Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 27 Italy Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 28 Spain Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 29 Rest of Europe Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 30 China Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 31 Japan Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 32 India Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 33 South Korea Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 34 Southeast Asia Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 35 Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 36 Latin America Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 37 Brazil Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 38 Mexico Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 39 Rest of Latin America Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 40 Middle East & Africa Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 41 GCC Countries Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 42 South Africa Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)
FIG. 43 Rest of Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Polycystic Ovary Syndrome (PCOS) Market
TABLE 2 Global Polycystic Ovary Syndrome (PCOS) Market, by Competitive Benchmarking, 2021
TABLE 3 Global Polycystic Ovary Syndrome (PCOS) Market, by Geographical Presence Analysis, 2021
TABLE 4 Global Polycystic Ovary Syndrome (PCOS) Market, by Key Strategies Analysis, 2021
TABLE 5 Global Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 6 Global Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 7 North America Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 8 North America Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 9 North America Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
TABLE 10 US Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 11 US Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 12 Canada Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 13 Canada Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 14 Europe Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 15 Europe Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 16 Europe Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
TABLE 17 Germany Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 18 Germany Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 19 France Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 20 France Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 21 UK Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 22 UK Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 23 Italy Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 24 Italy Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 25 Spain Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 26 Spain Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 27 Rest of Europe Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 28 Rest of Europe Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 29 Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 30 Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 31 Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
TABLE 32 China Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 33 China Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 34 Japan Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 35 Japan Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 36 India Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 37 India Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 38 South Korea Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 39 South Korea Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 40 South East Asia Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 41 South East Asia Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 42 Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 43 Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 44 Latin America Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 45 Latin America Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 46 Latin America Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
TABLE 47 Brazil Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 48 Brazil Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 49 Mexico Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 50 Mexico Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 51 Rest of Latin America Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 52 Rest of Latin America Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 53 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 54 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 55 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, by Country, 2016-2028 (US$ Bn)
TABLE 56 GCC Countries Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 57 GCC Countries Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 58 South Africa Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 59 South Africa Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)
TABLE 60 Rest of Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, By Drug Class, 2016-2028 (US$ Bn)
TABLE 61 Rest of Middle East and Africa Polycystic Ovary Syndrome (PCOS) Market, By End User, 2016-2028 (US$ Bn)

Frequently Asked Questions

How does COVID-19 Impact the global polycystic ovary syndrome (PCOS) market?

The COVID-19 outbreak had a significant influence on the healthcare industry. The pandemic negatively impacted the market for treating polycystic ovarian syndrome (PCOS), which had an impact on numerous surgical procedures, including laparoscopic ovarian syndrome.

Which is the leading market for polycystic ovary syndrome (PCOS)?

North America accounted for the highest share in the global polycystic ovary syndrome treatment market.

What are the key drivers for the growth of the polycystic ovary syndrome (PCOS) market?

Surging cases of PCOS and expanding the healthcare industry are the major factors driving the market’s growth.

Which is the major segment in the polycystic ovary syndrome (PCOS) market by drug class?

Insulin Sensitizing Agent segment had a major market revenue share in 2021. Besides, it is also projected to witness the fastest growth.

Which is the major segment in polycystic ovary syndrome (PCOS) Market by End User?

The Hospital Pharmacies segment had a major share in the global market in 2021 and is projected to continue its dominance over the forecast period.

Qatar Dental Care Market

Published:
Report ID: 30608

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Hepatic Encephalopathy Market

Published:
Report ID: 33664

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Guidewires Market

Published:
Report ID: 6790

3D Printing for Personalized Healthcare Market

Published:
Report ID: 33603

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

In Vitro Diagnostic (IVD) Kit Market

Published:
Report ID: 33580

North America Medical Headgears Market

Published:
Report ID: 33554

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN